The cost of product development of Bt corn event MON810 in the Philippines

AgBioForum

Volumn 10, Issue 1, 2007, Pages 19-32

  Manalo, Abraham J ^a   Ramon, Godfrey P ^a  

^a Biotechnology Coalition of the Philippines ^*  (Philippines)

Author keywords

Bt corn MON810; Department of Agriculture (DA); Insect Resistance Management (IRM); Lindahl factor; National Committee on biosafety of the Philippines (NCBP); Product development; Scientific and Technical Review Panel (STRP)

Indexed keywords

HEXAPODA; ZEA MAYS;

EID: 36049030422     PISSN: None     EISSN: 1522936X     Source Type: Journal    
DOI: None     Document Type: Review

References (16)

1. Adams, C.P., & Brantner, V.V. (2004). Estimating the costs of new drug development: Is it really $802m? Federal Trade Commission, December.
2. Detering, D. (2001). How to charge Lindahl prices for IP goods. In Ökonomie der medieninhalte. allokative effizienz und soziale chancengleichheit in den neuen medien. [Economy of content media. Allocative efficiency and social equal chances in the new media]. Herausgegeben von Klaus Backhaus, Heinz-Lothar Grob, Bernd Holznagel, Wolfram-Manfred Lippe und Gerhard W. Wittkämper. Telekommunikation und Multimedia. Band 6. Münster: LIT. Zugl.: Münster (Westf.), Univ., Diss., 1999.
3. DiMasi, J.A., Hansen, R.W., & Grabowski, H.G. (2003). The price of innovation: New estimates of drug development costs. Journal of Health Economics, 22(2), 151-185.
4. DiMasi, J.A., Hansen, R.W., Grabowski, H.G., & Lasagna, L. (1991). Cost of innovation in the pharmaceutical industry. Journal of Health Economics, 10(2), 107-142.
5. Frantz, S. (2003). Why are clinical costs so high? Nature Reviews: Drug Discovery, 2(11), 851-852.
6. Grabowski, H.G., & Vernon, J.M. (1990). A new look at the returns and risks to pharmaceutical R&D. Management Science, 38(7), 804-821.
7. Intriligator, M.D. (1996). Drug evaluations: Type I vs. type II errors (Paper 96-2). Los Angeles: University of California Los Angeles, UCLA Research Program in Pharmaceutical Economics and Policy.
8. Hansen, R.W. (1979). The pharmaceutical development process: Estimates of current development costs and times and the effects of regulatory changes. In R.I. Chien (Ed.), Issues in Pharmaceutical Economics. Lexington, MA: Lexington Books.
9. Harrington, W., Morgenstern, R., & Nelson, P. (1999). On the accuracy of regulatory cost estimates (Discussion Paper 99-18). Resources for the Future Discussion Paper. Washington, D.C.: Author.
10. Pardey, P.G., & Beintema, N.M. (2001). Slow magic: Agricultural research a century after mendel. Washington, D.C: International Food Policy Research Institute.
11. Philippine National Economic and Development Authority (2004). ICC project evaluation procedures and guidelines. Retrieved December 18, 2005, from http://www.neda.gov.ph/ progs_prj/ICC/Latest_ICC_FormsJan_2004/ ICC%20PROJECT%20EVALUATION%20PROCEDURES %20AND%20GUIDELINES.pdf.
12. Schnee, J.E. (1972). Development cost: Determinants and overruns. Journal of Business, 45(3), 347-374.
13. US Congress, Office of Technology Assessment (1993). Pharmaceutical R&D: Costs, risks and rewards (OTA-H-522). Washington, DC: US Government Printing Office.
14. Wiggins, S.N. (1987). The cost of developing a new drug. Washington, DC: Pharmaceutical Manufacturers Association.
15. Zepeda, J.F. (2005, January). Methodology, research, policy analysis and implications of biosafety regulatory costs studies in Asia and Africa. Paper presented at the SEARCA Agriculture and Development Seminar Series, Los Baños, Laguna, Philippines.
16. Zepeda, J.F., Cohen, J., & Komen, J. (2003, July). Biotechnology, biosafety and regulatory costs. Paper presented at the 7th ICABR International Conference on Public Goods and Public Policy for Agricultural Biotechnology, Ravello, Italy.